Skip to search formSkip to main contentSkip to account menu

Disopyramide:SCnc:Pt:Ser/Plas:Qn

Known as: Disopyramide SerPl-sCnc, Disopyramide [Moles/volume] in Serum or Plasma, Disopyramide:Stof concentratie:Moment:Serum of plasma:Kwantitatief 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
SummaryIn order to choose the most appropriate antiarrhythmic agent, the basic haemodynamic characteristics of class I… 
2005
2005
SummaryThe acute effects of i.v. disopyramide (1.5 mg/kg) on the hemodynamics of postischemic hearts were investigated in… 
2005
2005
The pharmacokinetics and bioavailability of total (bound plus unbound) and unbound disopyramide were compared following the… 
2002
2002
  • A. Schuchert
  • Herzschrittmachertherapie und Elektrophysiologie
  • 2002
  • Corpus ID: 28931324
Zusammenfassung Das Behandlungsziel bei Patienten mit rezidivierenden neurokardiogenen (= vasovagalen) Synkopen ist, das erneute… 
1993
1993
Objective: To examine the effects of saturable plasma binding on the pharmacokinetics of immediate‐release (IR) and controlled… 
1989
1989
The use of disopyramide is often limited because of adverse hemodynamic or electrophysiologic side effects. We compared the S… 
1988
1988
Die Verbesserung der Hamodynamik in Ruhe und unter Belastung ist eines der Hauptziele antiarrhythmischer Therapie. Dabei wird… 
1983
1983
  • J. Huang, S. Oie
  • Research communications in chemical pathology and…
  • 1983
  • Corpus ID: 32052175
The influence of altered serum protein binding on the pharmacologic response to R- and S-disopyramide was studied in the rabbit…